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Abstract Introduction In the pregnancy-puerperal cycle, women may develop complications
that require admission to the Intensive Care Unit (ICU). Thus, special attention to
pharmacotherapy is necessary, particularly to potential drug interactions (PDIs) and to
the effect of the drugs on the fetus and newborn.
Objective The aim of this study was to determine the profile of PDIs and the potential
risk of drugs used during pregnancy and breastfeeding among patients admitted to the
ICU.
Methods We conducted an observational, cross-sectional and prospective study,
including pregnant and breastfeeding women admitted to the ICU at the Women’s
Hospital of a university in the city of Campinas, Brazil, for one year. Online databases
were used to identify and classify the PDIs and the potential risk of the drugs used
during pregnancy and breastfeeding.
Results We evaluated 305 prescriptions of 58 women, 31 pregnant and 27 breast-
feeding, and 284 (91%) prescriptions presented PDIs. A total of 175 different
combinations of PDIs were identified in the prescriptions, and adverse effects caused
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In women’s health care, special attention is required during
the pregnancy-puerperium cycle, when a woman can deve-
lop several obstetric and non-obstetric complications that
can require admission to an Intensive Care Unit (ICU).1–5
During hospitalization, pregnant and breastfeeding wo-
men use a complex pharmacotherapy with many drugs
prescribed, leading to potential drug interactions (PDIs).
Potential drug interactions are defined as pharmacological
or clinical responses to the administration of two or more
drugs, which is different from the response when these
agents are used individually.6 Due to the highly complex
environment of the ICUs and to the great number of medica-
tions that most critical patients need, their prescriptions are
more susceptible to have potential drug–drug interactions.7
A study conducted by Plaza et al8 showed that 23% of
clinically significant adverse events observed in a studied
ICU in Chile were related to drug interactions.
The use of drugs during pregnancy calls for special atten-
tion because it may result in damage to the mother and the
fetus. In order to avoid undesirable side effects, especially in
the first trimester, the appropriate selection of drugs accor-
ding to the gestational age is required. Reducing medication
errors and improving patient safety are the important areas
of discussion here.9,10
Risk evaluation of the drugs used during breastfeeding in
postpartumpatients admitted to the ICU requires knowledge
of the factors that determine if amedication is safe to be used
during this period, such as lipid solubility, the ability to bind
protein, the level of ionization, the half-life, and the bioavai-
lability of these drugs. These concepts are relevant because
some drugs are excreted in the breastmilk and thereforemay
cause problems to the newborn.9–14
The aim of this study was to determine the profile of PDIs
and the risk categorization of the drugs used during preg-
nancy and breastfeeding found in the prescriptions of the
women admitted to an ICU specialized in women’s health.
total of 26 (1.4%) PDIs were classified as contraindicated. We identified 15 (13.8%)
drugs prescribed with risk D, and 2 (1.8%) with risk X for pregnant women, as well as 4
(4.9%) drugs prescribed with high risk for breastfeeding women.
Conclusions This study demonstrates that there is a high incidence of PDIs in
prescriptions. Most drugs used by pregnant and breastfeeding women at the ICU
did not present serious risks to their fetus and newborns, but sometimes drugs with risk
D or X are necessary in the course of the treatment.
Resumo Introdução No ciclo gravídico-puerperal, as mulheres podem desenvolver complica-
ções que necessitam de internação na Unidade de Terapia Intensiva (UTI). Assim, é
necessária uma atenção especial à farmacoterapia, particularmente às interações
medicamentosas potenciais (IMPs) e ao risco dos medicamentos para o feto e o recém-
nascido.
Objetivo Determinar o perfil das IMPs e o risco potencial dos medicamentos
utilizados durante a gravidez e a amamentação entre as mulheres internadas em UTI.
Métodos Foi realizado um corte transversal e prospectivo, observacional, incluindo
mulheres grávidas e lactantes internadas na UTI do Hospital da Mulher de uma
universidade de Campinas durante um ano. Bases de dados online foram usadas
para identificar e classificar as IMPs e o potencial risco de uso demedicamentos durante
a gravidez e a amamentação.
Resultados Foram avaliadas 305 prescrições de 58 mulheres, 31 grávidas e 27
lactantes, e 284 (91%) prescrições apresentaram IMPs, sendo que 175 combinações
diferentes de IMPs foram identificadas nas prescrições, e não foram observados efeitos
nocivos pelo uso concomitante dos medicamentos na prática clínica. Um total de 26
(1,4%) IMPs foram classificadas como contraindicadas. Foram identificados 15 (13,8%)
medicamentos prescritos com risco D, e 2 (1,8%) com risco X para mulheres grávidas, e
foram identificados 4 (4,9%) medicamentos prescritos como de alto risco para as
mulheres que estavam amamentando.
Conclusões Este estudo demonstra que há uma alta incidência de IMPs nas prescri-
ções. A maioria dos medicamentos utilizados por mulheres grávidas e lactantes em UTI
não apresentou sérios riscos para o feto e o recém-nascido, mas às vezes são
necessários medicamentos categorizados como risco D ou X.
Palavras-chave
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Rev Bras Ginecol Obstet Vol. 39 No. 6/2017
Potential Drug Interactions and Drug Risk during Pregnancy and Breastfeeding Ferracini et al. 259
Methods
Study Design and Participants
We conducted a prospective cross-sectional study in the ICU
at the Women’s Hospital of a university in the city of
Campinas, Brazil, a referral center in women’s health. This
ICU has 6 adult beds, and serves acutely ill women with
obstetric, gynecological, and oncological morbidities who
require intensive life support. This ICU has a multidisci-
plinary team composed of members from different health-
care professions, such as physicians, nurses, pharmacists,
physiotherapists, psychologists and nutritionists. Pregnant
or breastfeeding women over 18 years old admitted to the
ICU from Monday to Friday were included. Women in the
postpartum period, non-breastfeeding, and patients who
were admitted to the ICU and discharged on weekends
were excluded from the study.
Data Collection Procedures
Electronic prescriptions of the patients throughout the
course of one year (from October 2012 to September 2013)
were evaluated through the computerized system that
stores data, enabling the search by the date of the presc-
riptions and the inpatient unit (one prescription was
evaluated per day of hospitalization, per patient). Patient
data comprised of identification (number of hospital
record); age (in years); number of prescriptions; name
of each drug prescribed; number of units prescribed; and
average number of drugs per prescription. The PDIs and
the risk categorization of the drugs during pregnancy and
breastfeeding found in the prescriptions were quantified
and classified.
For the identification and classification of the PDIs, an
interactive system called DrugReax System was used. This
system is part of the international database called Thomson
Micromedex. To use this system, each generic name of the
drugs prescribed must be entered in the system.15 The
system returns with a drug-drug combination showing the
interactions. The severity of each interaction is classified as
secondary, moderate, important and contraindicated (“se-
condary” interactions generally do not require a major inter-
vention in the treatment, and “contraindicated” indicates
that the drugs are contraindicated for concomitant use). Its
most likely mechanism is a review of the documentation
regarding this drug interaction, onset and the available
literature.15 The therapeutic classes and affected organs
involved in the PDIs were classified according to the first
level of the Anatomical Therapeutic Chemical (ATC) Classi-
fication System.16
To analyze the risk of the drugs to the pregnancy, the
classification of the Food and Drug Administration (FDA) was
adopted. It consists of five categories: A, B, C, D and X; A is the
safest, and X is absolutely contraindicated.17 The risk of the
drugs ingested by a newborn through breastfeeding was
consulted in the database called E-lactancia.org.18 The risk
in this database is categorized as “very low risk,” “low risk,”
“high risk” and “very high risk”; “very low risk” is the safest
category, and “very high risk” is absolutely contraindicated.
Furthermore, this database shows alternatives to the pa-
tients’drug therapy, enabling rapid decisionwhen choosing a
safe medication.18
Data Processing and Analysis
The PDIs and the risk of specific drugs during pregnancy and
breastfeeding were estimated and classified in spreadsheets
using the Microsoft Excel (Microsoft, Redmond, WA, US)
software, so all data was tabulated and analyzed. The desc-
riptive analysis to evaluate the frequencies (n) and percenta-
ges (%) for the categorical variables and the descriptive
statistics for the numeric variables were performed. The
total of PDIs, the risks of the drugs and their severity, and
the average of the prescribed drugs during the hospital stay,
all for each patient, were calculated and evaluated to estab-
lish the prevalence of the PDIs and the risk of using specific
drugs during pregnancy and breastfeeding. The present
study was approved by the Research Ethics Committee of
the institution (CAAE: 1187.0.146.000–11). The present
study followed the checklist research of the strengthening
the reporting of observational studies in epidemiology
(STROBE) statement.19
Results
Demographic Characteristics and Profile Prescriptions
During the period from October 2012 to September 2013, 58
patients were admitted to the ICU; 31 pregnant and 27
breastfeeding women. The average age was 30.2  6.0
(average  standard deviation [SD]; between 19 and 46 years
old); the number of days in the ICUwas 5.3  9.1,with a range
oneof1 to58daysof stay; and1patientdied in thepostpartum
period of uncontrolled systemic lupus erythematosus.
Themost common reasons for admissions were: hyperten-
sive disorders (69.0%), post-operative postpartum (23.2%), and
sepsis (7.8%). A total of 34 patients had no comorbid condi-
tions;17patientsshowed1comorbidcondition, and7patients
hadmore than 1 comorbid conditions.►Table 1 demonstrates
the demographic characteristics of the study population.
We evaluated 305 prescriptions (200 for pregnant women
and 105 for breastfeeding women), with a mean of 5.7  9.1
prescriptions per patient. A total of 138 different drug types
were prescribed, with an average of 13.9  3.2 drugs per
prescriptions. The most prescribed drugs for the pregnant
women were: dipyrone, enoxaparin and hydralazine (6.5%,
5.9% and 3.7% respectively). For the breastfeeding women,
the most prescribed drugs were: dipyrone, enoxaparin and
simethicone (7.2%, 5.9% and 4.4%, respectively).
Potential Drug Interactions
Among the 138 different drugs prescribed, 97 drugs (70.3%)
were involved in at least one PDI, and 284 (91%) prescriptions
had PDIs, totalizing 1,849 PDIs in all prescriptions (6.0  5.7
per prescription), with a range of 1 to 17 PDIs. Among the
PDIs found in this study, 850 were moderate (632 [47.1%] for
the pregnant women, and 218 [42.8%] for the breastfeeding
women); 589 were important (497 [29.6%] for the pregnant
women, and 192 [37.8%] for the breastfeeding women); 384
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were classified as secondary (298 [22.2%] for the pregnant
women, and 86 [17.0%] for the breastfeeding women); and
26 were contraindicated (14 [1.0%] for the pregnant women,
and 12 [2.4%] for the breastfeeding women).
A total of 175 different combinations of PDIs were identi-
fied in the prescriptions, with 6 combinations considered
contraindicated (4 for the pregnant women, and 2 for the
breastfeeding women), 55 considered important (40 for the
pregnant women, and 28 for the breastfeeding women), 90
consideredmoderate (71 for the pregnant women, and 42 for
the breastfeeding women), and 24 considered secondary (22
for the pregnant women, and 10 for the breastfeeding
women). These PDIs were not actually observed in
practice. ►Table 2 shows the most frequent PDIs.
Themain therapeutic classes and affected organs involved
in the PDIs were those used for the nervous system (21;
26.6%), cardiovascular system (16; 20.3%), blood and the
blood forming organs (13; 16.5%), anti-infectives for syste-
mic use (11; 13.9%) and alimentary system (8; 10.1%).
Risk Categorization of Drugs during Pregnancy and
Breastfeeding
Through the prescriptions, it was also possible to classify and
identify the risk categorization of the drugs prescribed du-
ring pregnancy and breastfeeding, and the most frequently
prescribed drugs that women were exposed to (►Table 3).
A total of 127 types of drugs were prescribed by the
doctors for the pregnant group, and 109 drugswere classified
according to the FDA risk classification. A total of 18 drugs
used in Brazil are not classified by the FDA, including
dipyrone. The most frequently prescribed drugs were those
classified as category C.
Drugs with a negative risk–benefit (FDA category D or X)
ratiowere prescribed to 19women (27.6%): category D drugs
were prescribed to 16 patients (66.0%), and those classified
as category X were prescribed to 3 patients (6.0%). Drugs
prescribed during the second trimester and classified as risk
D and X were found in 14 prescriptions (12 belonging to
pregnant women, and 2 belonging to breastfeeding women);
Table 2 Characteristics and frequency (% in the study) of the prevalence of PDIs in the prescriptions
Pregnant Women
Drugs involved Severity Warning Total (%)
dipyrone x enoxaparin sodium Important Bleeding 152 (11.3)
dipyrone x propranolol Moderate Decreased antihypertensive effect 45 (3.4)
amlodipine x dipyrone Secondary Gastrointestinal hemorrhage 43 (3.2)
hydralazine x propranolol Moderate Increased risk of propranolol adverse effects 39 (2.9)
furosemide x hydralazine Moderate Enhanced diuretic response to furosemide 38 (2.8)
Breastfeeding Women
Drugs involved Severity Warning Total (%)
dipyrone x enoxaparin sodium Important Bleeding 83 (16.3)
captopril x dipyrone Moderate Decreased antihypertensive efficacy 29 (5.7)
amlodipine x dipyrone Secondary Gastrointestinal hemorrhage 24 (4.7)
fentanyl x midazolam Important Increased risk of CNS depression 19 (3.7)
dipyrone x propranolol Moderate Decreased antihypertensive effect 15 (2.9)
Abbreviations: CNS, central nervous system; PDIs, potential drug interactions.
Notes: Severity classification and other information available in Micromedex (Truven Health Analytics, Ann Arbor, MI, US).
Number of times in which the PDIs appeared in prescriptions.
Table 1 Demographic characteristics of the study population
Characteristics No. (%)
Patients 58
Pregnant women 31 (53.5)
Breastfeeding women 27 (46.5)
Age (years) (mean  standard deviation) 30.2  6.6




2nd trimester 18 (58.1)









Chronic obstructive pulmonary disease 2 (7.4)
Other conditions 8 (29.6)
Note: Presence of underlying diseases in the patients.
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during the third trimester, those drugs were found in 2
prescriptions of pregnant women, and in 1 prescription of
a breastfeeding woman.
For the breastfeeding women, 94 different drugs were
prescribed, and 81 were classified by the E-lactancia.org
database. Some drugs, such as mineral oil, oxytocin, and
pindolol, were not found in this database, and were not
classified. Many of the most frequently prescribed drugs
were classified as very low risk.
High risk drugs were found in 4 prescriptions of breast-
feeding women (14.8%) and low risk drugs were found in 24
prescriptions (22.9%).
Discussion
Our study confirms that the prescriptions for pregnant and
breastfeeding women hospitalized in an ICU, which mainly
included anti-infective drugs for systemic use, and nervous
system and cardiovascular system drugs, have a high inci-
dence of PDIs. However. most of the drugs used by these
women in the ICU did not present serious risks to their fetus
and newborns.
The average age of the pregnant and breastfeeding
patients who needed ICU admission was  30 years, and
a similar age was found in other studies in which the
patients required admission to the obstetric ICU.20,21 In
the present study, the most common cause of ICU admission
was pregnancy-induced hypertensive disorders, which is in
agreement with the study by Demirkiran et al,22 who
analyzed 125 patients admitted to the ICU. Overall, few
women become sufficiently ill to require hospitalization in
an ICU, but the normal adaptive physiology of the preg-
nancy and the presence of a fetus or breastfeeding a new-
born make these women different from other critically ill
patients. Furthermore, the short ICU stay ( 5 days) sug-
gests that most of these patients did not have major
complications.23,24
A total of 91% of the prescriptions presented at least one
PDI, and all 4 classifications are present in the studied PDIs,
(from contraindicated to secondary), and the most frequent
interactions are moderate. The most recurrent moderate PDI
observed was the interaction between dipyrone and capto-
pril or propranolol. This PDIs have theoretical clinical rele-
vancy, as caution in the use of both drugs is recommended: to
monitor the antihypertensive efficacy and assess renal func-
tion periodically, but do not offer significant risks to the
patients. Important PDIs were the second most prevalent,
and themost frequent was the interaction between dipyrone
and enoxaparin. The clinical management states the suspen-
sion of dipyrone or, if maintained, a continuous monitoring
of bleeding episodes is necessary.7,15 Despite this clinical
management, the choice of anticoagulant in this setting is
based upon careful consideration of the maternal and fetal
risks discussed with the patient. Considering this combina-
tion, which is classified as important, the symptoms should
be monitored to avoid the possible adverse events described
in the literature.7
Numerous drug classes are specially relevant for the high
risk of interactions, and, in many cases, the management of
the interactionwould depend on the patients’ clinical status,
the routes and timing of drug administration, drug doses, or
the response/lack of response to the current pharmacothe-
rapy.25 Nervous system drugs were the most related with
PDIs when grouped by ATC classification, and this high
number can be justified considering that sedation and anal-
gesia are essential components in the treatment of patients
in intensive care.26 Drugs that act on the cardiovascular
system were the second most related to PDIs when grouped
by ATC classification. A study in a teaching hospital’s ICU in
Brazil demonstrated that the prescription of antihyperten-
sive drugs is also considered the main cause of drug inter-
actions among prescription drugs.27
Even though this research showed the high number of
important, moderate and secondary PDIs found in the
Table 3 Risk categorization of drugs used during pregnancy and breastfeeding, and some drugs implicated
Pregnant Women
Risk categorization Patients Drugs (%) Type of drugs
A 25 3 (2.8) magnesium sulfate, levothyroxine, folic acid.
B 31 29 (26.6) enoxaparin sodium, methyldopa, dimenhydrinate, metoclopramide, ranitidine.
C 31 60 (55.0) omeprazole, hydralazine, dextrose, methadone, potassium chloride.
D 16 15 (13.8) phenytoin, lorazepam, midazolam, clonazepam, diazepam
X 3 2 (1.8) misoprostol, pravastatin.
Breastfeeding Women
Risk Categorization Patients Drugs (%) Type of drugs
Very low risk 27 58 (71.6) enoxaparin sodium, simethicone, metoclopramide, bromopride, magnesium
sulfate.
Low risk 27 18 (22.2) dipyrone, tramadol, furosemide, ranitidine, dimenhydrinate.
High risk 4 4 (4.9) chloramphenicol, nitroprusside, diazepam, dexchlorpheniramine,
prometazine.
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prescriptions (►Table 2), this does not necessarily corre-
spond to the clinical relevancy, and the PDIs were not
actually observed in practice at this Brazilian ICU. Thereby,
even though some studies have reported drug interactions
with some drug classes prescribed to pregnant and breast-
feeding women, our findings prove that ours is a relevant
study for this population in critical state, and it is important
to support health professionals in making therapy
decisions.28–30
Regarding the risk categorization for the pregnant wo-
men, most medications used were from category C, followed
by category B, and similar results were found by a study
conducted in a teaching hospital in Croatia in which the
majority of pregnant women were exposed to category C
(56%) and B (41%) drugs.31 A small number of different drugs
were responsible for the majority of prescriptions for cate-
gory D drugs, as well as for category X drugs during the
analysis of the electronic prescriptions. Category D also
comprehended a small number of different drugs, notably
benzodiazepines (lorazepam, midazolam, clonazepam). It is
clear that some category D drugs are being appropriately
used considering the maternal benefit, such as antiepileptic
drugs (phenytoin).31,32 In this research, the drugs classified
as category X include misoprostol. Despite the use of miso-
prostol not being authorized by the FDA, this drug, classified
as risk X, is used for cervical ripening and labor induction,
and its use is oriented by various guidelines.32,33 Its use in the
puerperium is also safe and indicated in cases of postpartum
hemorrhage and secondary to uterine atony.32 Other drugs
classified by the FDA as risk X can be cited, such as pravasta-
tin, which was prescribed for a pregnant patient during
hospitalization as a substitute for omega 3.21,34
The breastfeeding women included in the study were
women declared able to breastfeed by the multidisciplinary
team, even as they required intensive care. In the study
period, 22 non-breastfeeding women admitted to the ICU
were excluded. During the study, we observed that most of
the drugs used by the breastfeeding women posed no serious
risks to the newborn, since the “very low risk” category was
themost prevalent, followed by the “low risk” category. Most
drugs considered as “high risk” are being appropriately
prescribed, taking into consideration the maternal benefit,
but other drugs, such as diazepam, could be substituted by
safer alternatives, which demonstrates that the clinical
pharmacists of the ICU could provide direct patient
care.18,34 There are no researches with a classification of
drug safety during breastfeeding according to the E-lactancia
database.18
Among the various publications that report on the use of
drugs during breastfeeding, the reference basic studies used
are provided by the American Academy of Pediatrics
(AAP).11,35,36 According to the AAP, certain classes of drugs
can be problematic, either because of accumulation in the
breast milk, or due to their effects on the nursing infant or
mother. The most common drugs include pain medications,
antidepressants, and drugs to treat substance/alcohol abuse
or smoking.35 In the E-lactancia database, the classes of drugs
that can be problematic to the newborn are the same drugs
according to the AAP, the only thing that differs is the risk
categorization.
The main strength of this study is its setting: the ICU of a
Brazilian teaching hospital for women’s healthcare, which
treats pregnant and breastfeeding women. Moreover, this
study had other advantages: the presence of electronic
prescriptions in the teaching hospital, and the access to
databases for evaluating the drugs presented in the prescrip-
tions. A limitation of this study was that a pilot study to
sample the calculation was not performed. However, taking
into consideration the period of a year of study, and after the
data analysis, this sample could be considered significant,
because of the number of patients, the number of beds in the
ICU, and the number of prescriptions analyzed.
Conclusion
This study demonstrated that there is a high incidence of
PDIs in the pharmacotherapy prescribed to pregnant and
breastfeeding women. This study also showed that most of
the drugs used during pregnancy and breastfeeding at the
ICU did not present serious risks to the fetus and the
newborns.
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